Treatment of pyorrhoea associated bone loss around teeth using gel

Efficacy of recombinant human fibroblast growth factor gel in the management of intrabony defects - A randomised controlled, double blinded, clinical trial - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093190

Enrollment

Registered

2025-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Test group: Recombinant human fibroblast growth factor gel will be used as a biological agent for treatment of isolated intrabony defects in mandible combination with open flap debridem

Eligibility

Inclusion criteria

Inclusion criteria: With single intrabony defect In posterior mandible sites Sufficient soft tissue height and thickness at the defect site

Exclusion criteria

Exclusion criteria: Smokers Tobacco users Pregnancy Lactating mothers Not available for 24 months follow up Unwilling for periodic recall every 3 months

Design outcomes

Primary

Measure	Time frame
Radiographic bone fill Reduction in pocket probing depth Gain in clinical attachment levelTimepoint: Baseline, 3 Months, 6 Months, 12 Months	—

Secondary

Measure	Time frame
Longevity of tooth survival Reduction in mobility Incidence of complications Patient reported outcome measuresTimepoint: Baseline, 3 Months, 6 Months, 12 Months	—

Countries

India

Contacts

Public ContactLt Col Saravanan SP

Army Dental Centre Research Referral Delhi

saravananacademics@gmail.com9637110906

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026